We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)

This study has been terminated.
(lack of the subjects)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01766505
First Posted: January 11, 2013
Last Update Posted: March 14, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Chong Kun Dang Pharmaceutical
  Purpose
The purpose of this study is to compare efficacy and safety of candesartan and losartan in hypertension with heart failure.

Condition Intervention Phase
Hypertension Drug: Candemore tablet Drug: Cozzar tablet Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Open-label, Phase 4 Study to Evaluate Efficacy and Safety of Candesartan and Losartan in the Patients With Hypertension and Heart Failure.

Resource links provided by NLM:


Further study details as provided by Chong Kun Dang Pharmaceutical:

Primary Outcome Measures:
  • change from baseline average sitting DBP(diastolic blood pressure)at 16 weeks [ Time Frame: baseline, 16 weeks ]

Secondary Outcome Measures:
  • change from baseline average sitting DBP(diastolic blood pressure)at 8 weeks [ Time Frame: baseline, 8 weeks ]
  • change from baseline average sitting SBP(systolic blood pressure)at 8 weeks [ Time Frame: baseline, 8 weeks ]
  • change from baseline average sitting SBP(systolic blood pressure)at 16 weeks [ Time Frame: baseline, 16 weeks ]
  • ratio of normalize from baseline blood pressure at 16 weeks [ Time Frame: baseline, 16 weeks ]
    normalize means that sitting SBP and DBP is below 140mmHg and 90mmHg

  • response ratio from baseline blood pressure at 16 weeks [ Time Frame: baseline, 16 weeks ]
    response means that decrease in sitting DBP and SBP is above 10mmHg and 20mmHg

  • change from baseline LVEF(left ventricular ejection fraction at 16 weeks [ Time Frame: baseline, 16 weeks ]
  • change from baseline LVEDD(left ventricular end-diastolic diameter)at 16 weeks [ Time Frame: baseline, 16 weeks ]
  • change from baseline LV(left ventricular) mass at 16 weeks [ Time Frame: baseline, 16 weeks ]
  • change from baseline PWV(pulse wave velocity) mass at 16 weeks [ Time Frame: baseline, 16 weeks ]

Other Outcome Measures:
  • rate of adverse event [ Time Frame: up to 16 weeks ]
  • medication history [ Time Frame: up to 16 weeks ]

Enrollment: 32
Study Start Date: June 2012
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Candemore tablet
Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
Drug: Candemore tablet

Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.

dosage is depends on the sitting blood pressure.

Active Comparator: Cozzar tablet
Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
Drug: Cozzar tablet
Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure

Detailed Description:
This is a randomized, open-label, phase 4 study. wash out periods need at least 14 days if the patients take ARB or ACE inhibitor to control Blood pressure. Patients take Candemore or Cozzar once a day during 16 weeks.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male patients who aged above 19 and below 75
  • Patients with 90~109mmHg average sitting DBP on baseline
  • NYHA class 2~4
  • Patients who agreement with written informed consent

Exclusion Criteria:

  • above 110mmHg sitting DBP and/or 180mmHg sitting SBP
  • Patients who have difference values that above 20mmHg sitting SBP or 10mmHg sitting DBP in both arms on screening
  • Patients who have medical history that secondary hypertension or rule out secondary hypertension
  • malignant hypertension
  • symptomatic postural hypotension
  • right heart failure due to pulmonary disease
  • etc.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01766505


Locations
Korea, Republic of
Chunbuk National University Hospital
Chonju, Korea, Republic of, 561-712
Presbyterian Medical Center
Chunju, Korea, Republic of, 560-750
Chungnam national university hospital
Daejeon, Korea, Republic of, 301-721
The catholic university of Korea, Daejeon st. Mary's Hospital
Daejeon, Korea, Republic of, 301-723
Eulji University Hospital
Daejeon, Korea, Republic of, 302-799
Konyang university hospital
Daejon, Korea, Republic of, 302-718
Chunnam National University Hospital
Gwangju, Korea, Republic of, 501-757
Kwangju Christian Hospital
Gwangju, Korea, Republic of, 503-715
ST.Carollo hospital
Suncheon, Korea, Republic of, 540-719
Sponsors and Collaborators
Chong Kun Dang Pharmaceutical
Investigators
Principal Investigator: Myungho Jeong, phD Chonnam National University Hospital
  More Information

Responsible Party: Chong Kun Dang Pharmaceutical
ClinicalTrials.gov Identifier: NCT01766505     History of Changes
Other Study ID Numbers: m111HHF11F
First Submitted: January 10, 2013
First Posted: January 11, 2013
Last Update Posted: March 14, 2014
Last Verified: March 2014

Keywords provided by Chong Kun Dang Pharmaceutical:
hypertension, heart failure, candesartan, losartan

Additional relevant MeSH terms:
Hypertension
Heart Failure
Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Losartan
Candesartan
Candesartan cilexetil
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action